Event Videos

 

FAQ on Extra Hepatic Portal Venous Obstruction (EHPVO)

 

1.     What is EHPVO?

 

EHPVO is a condition in which there is a block of the major vessel that supplies blood to the liver i.e. the portal vein.  This vein carries all absorbed nutrients from intestines to liver for storage and further metabolism. It accounts for major (80%) of blood supply to liver. Any block in this vein especially in the portion of the vein located outside the liver causes a condition called as EHPVO.

 

2.     What causes EHPVO?

EHPVO or the block in the portal vein may be caused by:

http://www.ncbi.nlm.nih.gov/pubmed/25874508

Srivastava A, Mathias A, Yachha SK, Aggarwal R. Occult hepatitis B infectionin children with chronic liver disease. Eur J GastroenterolHepatol. 2015; 27(4):375-7.

Abstract

AIMS:

Occult hepatitis B infection (OBI) may adversely affect the outcome of patients with chronic liver disease (CLD). There are no data on OBI and CLD in children. This study determined the prevalence and effect of OBI in HBsAg-negative CLD children.

MATERIALS AND METHODS:

CLD children were prospectively evaluated with a demographic, clinical, and investigative proforma. All HBsAg-negative CLD cases were tested for exposure to hepatitis B (total anti-HBc, anti-HBs). Serum hepatitis B virus DNA was measured in exposed (total anti-HBc positive) patients.

Published on: 
Apr-2015

Surce : http://zeenews.india.com/news/health/health-news/financial-support-for-v...

India will continue to get financial assistance from Gavi, a global alliance for vaccination and immunisation, only till 2020 because as the country develops it will have to pay for its vaccines.

Switzerland-based Gavi is on a drive to increase its global immunisation programme in which India has been an important partner.

"India is getting to a point where it will enter the period of graduating from Gavi's support, probably in 2016," Gavi Chief Executive Officer Seth Berkley told PTI.

http://www.ncbi.nlm.nih.gov/pubmed/25825851

Van Biervliet S, Küry S, De Bruyne R, Vanakker OM, Schmitt S, VandeVelde S,Blouin E, Bézieau S. Clinical zinc deficiency as early presentation of Wilsondisease. J PediatrGastroenterolNutr. 2015;60(4):457-9.

Abstract
Wilson disease is a rare autosomal recessive disorder of the copper metabolism caused by homozygous or compound heterozygous mutations in the ATP-aseCu(2+) transporting polypeptide (ATP7B) gene. The copper accumulation in different organs leads to the suspicion of Wilson disease. We describe a child with clinical zinc deficiency as presenting symptom of Wilson disease, which was confirmed by 2 mutations within the ATP7B gene and an increased copper excretion.

Published on: 
Apr-2015



Chandigarh



Dr. BR Thapa

Professor and Head,

Division of Pediatric Gastroenterology, Hepatology and nutrition,

PGIMER, Chandigarh



Delhi



Dr. Seema Alam

Additional Professor

Department of Pediatric Hepatology

Institue of Liver and Billiary Sciences,

New Delhi



Dr. Dinesh Rawat

Department of Pediatric Hepatology

Institue of Liver and Billiary Sciences,

New Delhi



Dr. Anupam Sibal

http://www.ncbi.nlm.nih.gov/pubmed/25874510

Rengasamy S, Ali SM, Sistla SC, Lakshmi CP, Harichandra Kumar KT. Comparisonof 2 days versus 5 days of octreotide infusion along with endoscopic therapy in preventing early rebleed from esophageal varices: a randomized clinical study. Eur J GastroenterolHepatol. 2015; 27(4):386-92.

Abstract

BACKGROUND:

Published on: 
Apr-2015

http://www.ncbi.nlm.nih.gov/pubmed/25557690

Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L. Challenges andopportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology. 2015; 61(4):1392-405.

Abstract

Published on: 
Apr-2015

CLF Intro movie

Financial Aid Offered by Trusts

Follow us on: